N/A
Manufactured by Baxter Healthcare Corporation
42,356 FDA adverse event reports analyzed
Last updated: 2026-04-14
IFOSFAMIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Baxter Healthcare Corporation. The most commonly reported adverse reactions for IFOSFAMIDE include OFF LABEL USE, FEBRILE NEUTROPENIA, DISEASE PROGRESSION, NEUTROPENIA, DRUG INEFFECTIVE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for IFOSFAMIDE.
Out of 20,616 classified reports for IFOSFAMIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 42,356 FDA FAERS reports that mention IFOSFAMIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include OFF LABEL USE, FEBRILE NEUTROPENIA, DISEASE PROGRESSION, NEUTROPENIA, DRUG INEFFECTIVE, THROMBOCYTOPENIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Baxter Healthcare Corporation in connection with IFOSFAMIDE. Always verify the specific product and NDC with your pharmacist.